Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet

Publication ,  Journal Article
Armstrong, AJ
Published in: Oncology (Williston Park, N.Y.)
October 1, 2014

Duke Scholars

Published In

Oncology (Williston Park, N.Y.)

ISSN

0890-9091

Publication Date

October 1, 2014

Volume

28

Issue

10

Start / End Page

883
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J. (2014). In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park, N.Y.), 28(10), 883.
Armstrong, A. J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park, N.Y.) 28, no. 10 (October 1, 2014): 883.
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park, NY). 2014 Oct 1;28(10):883.
Armstrong, A. J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park, N.Y.), vol. 28, no. 10, Oct. 2014, p. 883.
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park, NY). 2014 Oct 1;28(10):883.

Published In

Oncology (Williston Park, N.Y.)

ISSN

0890-9091

Publication Date

October 1, 2014

Volume

28

Issue

10

Start / End Page

883